A Phase 1 interventional study of ITF2357 10 mg/mL and ITF2357 10 mg/mL in Duchenne and Becker Muscular Dystrophy and Polycytemia Vera, sponsored by Italfarmaco. Completed at 1 site in Canada. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-11.
Sponsored by Italfarmaco · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 65 studies in Muscular Dystrophy, Duchenne with a site in Canada — 5 open to participants now, 14 under way, 8 of them phase 3. Muscular Dystrophy, Duchenne · Canada.
Among the 65 studies in Muscular Dystrophy, Duchenne with a site in Canada, this one is the 46th largest by enrollment of the 61 interventional ones that give a count, is one of 4 that started in 2021, is one of 4 in phase 1, and was the 53rd registered.
481 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.
Browse Muscular Dystrophy, Duchenne studies →5 of the 65 studies in Muscular Dystrophy, Duchenne with a site in Canada are open now. Recruiting first, the newest first:
Avidity Biosciences, Inc. · Sites in Canada, Australia, Belgium and 7 more countries
Ages 7–16 · Men only
Solid Biosciences Inc. · Sites in Canada, United States, Australia
Ages 7–11 · Men only
Solid Biosciences Inc. · Sites in Canada, United States, Italy and 1 more country
Ages 0–17 · Men only
Italfarmaco · Sites in Canada, Belgium, Czechia and 9 more countries
Ages 9–17 · Men only
Italfarmaco · Sites in Canada, United States, Belgium and 8 more countries
Ages 7+ · Men only
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 12 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
65 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 28 · Phase 3 31 · Phase 4 2
First in 2005; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 31 is above the median of 26 across 332 interventional studies indexed under Muscular Dystrophy, Duchenne.
Median enrollment 70 across the 61 interventional studies, 85 across the 3 observational. Of the 45 that completed or were terminated, 33 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
55 of 65 have an industry lead sponsor. The 10 most frequent:
Italfarmaco is the lead sponsor of 35 studies on the registry; 5 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
Italfarmaco has 8 studies filed under Muscular Dystrophy, Duchenne — fewer than ten, so there is no comparison to draw.
4 of the studies in Muscular Dystrophy, Duchenne with a site in Canada that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05881408Phase 3Sarepta Therapeutics, Inc.A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD) | 2027-05-31 |
| NCT05996003NS Pharma, Inc.NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD) | 2027-02-26 |
| NCT07287189Satellos Bioscience, Inc.Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients | 2027-03-31 |
| NCT06138639Solid Biosciences Inc.A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE) | 2027-05-06 |
Add all 4 to your calendar (.ics) → With an account.
Among the 65 studies in Muscular Dystrophy, Duchenne with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study will evaluate the effect of a therapeutic dose and a supratherapeutic dose of ITF2357 on the QT/QTc interval.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Healthy as defined by:
Non- female defined as:
Females of childbearing potential who are sexually active with a male partner must be willing to use one of the following acceptable methods throughout the study and for at least 90 days after the last study drug administration:
Male participants who are not vasectomized for at least 6 months, and who are sexually active with a female partner of childbearing potential (childbearing potential females are defined as women that are neither post-menopausal nor surgically sterile) must be willing to use one of the following acceptable contraceptive methods from the first study drug administration until at least 90 days after the last study drug administration:
Exclusion Criteria:
Any of the following abnormal laboratory test values at screening or at baseline (Day -1) of Period 1:
Use of medications for the timeframes specified below, with the exception of medications exempted by the Investigator on a case-by-case basis because they are judged unlikely to affect the pharmacokinetic profile of the study drug or participant safety (e.g., topical drug products without significant systemic absorption):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single dose of ITF2357 100 mg administered as 10 milliliters (mL) of ITF2357 10 milligrams per milliliter (mg/mL) oral suspension and 20 mL of placebo matched to ITF2357 oral suspension under fasting conditions on Day 1 of respective period as per the assigned treatment sequence.
Drug: ITF2357 10 mg/mL · Drug: Placebo
Participants will receive a single dose of ITF2357 300 mg administered as 30 mL of ITF2357 10 mg/mL oral suspension under fasting conditions on Day 1 of respective period as per the assigned treatment sequence.
Drug: ITF2357 10 mg/mL
Participants will receive a single dose of placebo matched to ITF2357 administered as 30 mL oral suspension under fasting conditions on Day 1 of respective period as per the assigned treatment sequence.
Drug: Placebo
Participants will receive a single dose of moxifloxacin 400 mg tablet under fasting conditions on Day 1 of respective period as per the assigned treatment sequence.
Drug: Moxifloxacin Hydrochloride
Drug page: Givinostat
Dose: 100 mg (administered as 10 mL); Dosage form: suspension; Route of administration: oral
Also known as: Givinostat
Drug page: Givinostat
Dose: 300 mg (administered as 30 mL); Dosage form: suspension; Route of administration: oral
Also known as: Givinostat
Dose: 20 mL; Dosage form: suspension; Route of administration: oral
Dose: 400 mg; Dosage form: tablet; Route of administration: oral
Dose: 30 mL; Dosage form: suspension; Route of administration: oral
Placebo-corrected Change From Baseline in Fridericia's Corrected QT Interval (QTcF)
The cardio-dynamic assessment was performed through 12-lead electrocardiogram (ECG) extracted from continuous recordings at pre-specified time points. Participants rested in supine position for at least 10 minutes prior to and 5 minutes after each time point for ECG extractions. The QT interval is the time from electrocardiogram Q wave to the end of the T wave corresponding to electrical systole. QT interval was corrected for heart rate using QTcF. Placebo-corrected change from baseline in QTcF (ΔΔQTcF) was calculated based on model-predicted effect.
Time frame: At 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, and 36 hours post-dose
Change From Baseline in QTcF Interval
The cardio-dynamic assessment was performed through 12-lead ECGs extracted from continuous recordings at pre-specified time points. Participants rested in supine position for at least 10 minutes prior to and 5 minutes after each time point for ECG extractions. QT interval was corrected for heart rate using Fridericia's correction (QTcF).
Time frame: At 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, and 36 hours post-dose
Change From Baseline in PR Interval
The cardio-dynamic assessment was performed through 12-lead ECGs extracted from continuous recordings at pre-specified time points. Participants rested in supine position for at least 10 minutes prior to and 5 minutes after each time point for ECG extractions. The PR interval is the time from the onset of the P-wave to the start of the next QRS complex, corresponding to the end of atrial depolarization and onset of ventricular depolarization.
Time frame: At 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, and 36 hours post-dose
Change From Baseline in QRS Interval
The cardio-dynamic assessment was performed through 12-lead ECGs extracted from continuous recordings at pre-specified time points. Participants rested in supine position for at least 10 minutes prior to and 5 minutes after each time point for ECG extractions. QRS interval is the time from electrocardiogram Q wave to the end of the S wave, corresponding to ventricle depolarization.
Time frame: At 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, and 36 hours post-dose
Change From Baseline in Heart Rate (HR) Interval
The cardio-dynamic assessment was performed through 12-lead ECGs extracted from continuous recordings at pre-specified time points. Participants rested in supine position for at least 10 minutes prior to and 5 minutes after each time point for ECG extractions. Baseline is defined as the last results (scheduled or unscheduled) obtained prior to drug administration in each period.
Time frame: At 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, and 36 hours post-dose
Placebo-corrected Change From Baseline in PR Interval
Placebo-corrected change from Baseline in PR, (ΔΔPR) was calculated based on model-predicted effect. PR interval was the time between the beginning of the P wave and the start of the QRS interval, corresponding to the end of atrial depolarization and onset of ventricular depolarization.
Time frame: At 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, and 36 hours post-dose
Placebo-corrected Change From Baseline in QRS Interval
Placebo-corrected change from baseline for QRS interval, (ΔΔQRS) was calculated based on model-predicted effect. QRS interval is the time from Q wave to the end of the S wave, corresponding to ventricle depolarization.
Time frame: At 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, and 36 hours post-dose
Placebo-corrected Change From Baseline in HR Interval
Placebo-corrected change from baseline in HR, (ΔΔHR) was calculated based on model-predicted effect.
Time frame: At 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, and 36 hours post-dose
Number of Participants With Changes in Categorical Outliers for QTcF, PR, and QRS Intervals in the ECG and HR
QTcF: Treatment-emergent value of greater than (\>) 450 and less than or equal to (\<=) 480 ms when not present at Baseline (new onset). Treatment-emergent value of \> 480 and \<= 500 ms when not present at Baseline (new onset). Treatment-emergent value of \> 500 ms when not present at Baseline (new onset). Increase of QTcF (ΔQTcF) from Baseline of \> 30 and \<= 60 ms. Increase of QTcF from Baseline \> 60 ms HR: Decrease of HR from Baseline \> 25% resulting in HR less than (\<) 50 bpm. Increase of HR from Baseline \> 25% resulting in HR \> 100 bpm. PR: Increase of PR from Baseline \> 25% resulting in PR \> 210 ms. QRS: Increase of QRS from Baseline \> 25% resulting in QRS \> 120 ms.
Time frame: Baseline, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, and 36 hours post-dose
Number of Participants With Treatment-Emergent Changes of T-Wave Morphology and U Wave Presence
T-wave abnormalities were categorized as follows: Normal T wave (+): Any positive T wave not meeting any criterion below. Flat T wave: T amplitude \< 1 mm (either positive or negative) including flat isoelectric line. Notched T wave (+): Presence of notch(es) of at least 0.05 mV amplitude on ascending or descending arm of the positive T wave. Biphasic: T wave that contains a second component with an opposite phase that is at least 0.1 mV deep (both positive/negative and negative/positive and polyphasic T waves included). Normal T wave (-): T amplitude that is negative, without biphasic T wave or notches. Notched T wave (-): Presence of notch(es) of at least 0.05 mV amplitude on descending or ascending arm of the negative T wave. U waves: Presence of abnormal U waves.
Time frame: Up to 44 days
Plasma Pharmacokinetic (PK): Area Under the Concentration-Time Curve From Time Zero to the Last Measurable Concentration (AUC0-t) of ITF2357 and Its Metabolites
The area under the concentration time curve (AUC) from time zero (= dosing time) to the last sampling time (tlast) at which the concentration is at or above the lower limit of quantification. AUC0-t was calculated using the mixed log-linear trapezoidal rule (linear up, log down). AUC0-t of ITF2357 and metabolites: ITF2374, ITF2375, ITF2440, ITF2563, and ITF2955 glucuronide were reported.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, 36, 48, 60, and 72 hours post-dose
Plasma PK: Area Under the Concentration-Time Curve From Time Zero to the Last Measurable Concentration (AUC0-t) of Moxifloxacin
The area under the concentration time curve (AUC) from time zero (= dosing time) to the last sampling time (tlast) at which the concentration is at or above the lower limit of quantification. AUC0-t was calculated using the mixed log-linear trapezoidal rule (linear up, log down).
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, 36, 48, 60, and 72 hours post-dose
Plasma PK: Area Under the Concentration-Time Curve From Time Zero to 12 Hours (AUC0-12) of ITF2357 and Its Metabolites
AUC0-12 was calculated using the trapezoidal method for ITF2357 and metabolites: ITF2374, ITF2375, ITF2440, ITF2563, and ITF2955 glucuronide. AUC0-12:: of ITF2357 and its metabolites: ITF2374, ITF2375, ITF2440, ITF2563, and ITF2955 glucuronide were reported.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, and 12 hours post-dose
Plasma PK: Area Under the Concentration-Time Curve From Time Zero to 12 Hours (AUC0-12) of Moxifloxacin
AUC0-12 was calculated using the trapezoidal method for Moxifloxacin.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8 and 12 hours post-dose
Plasma PK: Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of ITF2357 and Its Metabolites
AUC0-inf was calculated as AUC0-t + Clast/Kel, where Clast is the last measurable concentration. Elimination rate constant (Kel),was defined as the negative of the estimated slope of the linear regression of the in-transformed concentration versus time profile in the terminal elimination phase. AUC0-inf of ITF2357 and metabolites: ITF2374, ITF2375, ITF2440, ITF2563, and ITF2955 glucuronide were reported.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, 36, 48, 60, and 72 hours post-dose
Plasma PK: Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of Moxifloxacin
AUC0-inf was calculated as AUC0-t + Clast/Kel, where Clast is the last measurable concentration for Moxifloxacin.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, 36, 48, 60, and 72 hours post-dose
Plasma PK: Percentage of Residual Area for ITF2357 and Its Metabolites
Residual area was calculated as 100\*(1- AUC0-t / AUC0-inf) for ITF2357 and Metabolites: ITF2374, ITF2375, ITF2440, ITF2563, and ITF2955 glucuronide.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, 36, 48, 60, and 72 hours post-dose
Plasma PK: Percentage of Residual Area for Moxifloxacin
Residual area was calculated as 100\*(1- AUC0-t / AUC0-inf) for moxifloxacin.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, 36, 48, 60, and 72 hours post-dose
Plasma PK: Maximum Observed Plasma Concentration (Cmax) of ITF2357 and Its Metabolites
Cmax was calculated for ITF2357 and Metabolites: ITF2374, ITF2375, ITF2440, ITF2563, and ITF2955 glucuronide. Cmax was taken directly from the observed concentration-time curve.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, 36, 48, 60, and 72 hours post-dose
Plasma PK: Maximum Observed Plasma Concentration (Cmax) of Moxifloxacin
Cmax was calculated for moxifloxacin. Cmax was taken directly from the observed concentration-time curve.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, 36, 48, 60, and 72 hours post-dose
Plasma PK: Time of Observed Cmax (Tmax) of ITF2357 and Its Metabolites
Tmax was calculated for ITF2357 and Metabolites: ITF2374, ITF2375, ITF2440, ITF2563, and ITF2955 glucuronide. The time to reach the maximum observed plasma concentration obtained directly from plasma concentration time curve.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, 36, 48, 60, and 72 hours post-dose
Plasma PK: Time of Observed Cmax (Tmax) of Moxifloxacin
Tmax was calculated for Moxifloxacin. The time to reach the maximum observed plasma concentration obtained directly from plasma concentration time curve.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, 36, 48, 60, and 72 hours post-dose
Plasma PK: Elimination Rate Constant (Kel) of ITF2357 and Its Metabolites
Kel was defined as the negative of the estimated slope of the linear regression of the ln-transformed concentration versus time profile in the terminal elimination phase. Kel was calculated for ITF2357 and Metabolites: ITF2374, ITF2375, ITF2440, ITF2563, andITF2955 glucuronide.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, 36, 48, 60, and 72 hours post-dose
Plasma PK: Elimination Rate Constant (Kel) of Moxifloxacin
Kel was defined as the negative of the estimated slope of the linear regression of the ln-transformed concentration versus time profile in the terminal elimination phase. Kel was calculated for Moxifloxacin.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, 36, 48, 60, and 72 hours post-dose
Plasma PK: Elimination Half-life (T½ el) of ITF2357 and Its Metabolites
T½ el was calculated as ln(2)/kel for ITF2357 and Metabolites : ITF2374, ITF2375, ITF2440, ITF2563, ITF2955 glucuronide, and Moxifloxacin.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, 36, 48, 60, and 72 hours post-dose
Plasma PK: Elimination Half-life (T½ el) of Moxifloxacin
T½ el was calculated as ln(2)/kel for moxifloxacin.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, 36, 48, 60, and 72 hours post-dose
Plasma PK: Apparent Total Body Clearance (CL/F) of ITF2357 and Its Metabolites
CL/F was calculated as Dose/AUC0-inf for ITF2357 and Metabolites: ITF2374, ITF2375, ITF2440, ITF2563, and ITF2955 glucuronide.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, 36, 48, 60, and 72 hours post-dose
Plasma PK: Apparent Total Body Clearance (CL/F) of Moxifloxacin
CL/F was calculated as Dose/AUC0-inf for moxifloxacin.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, 36, 48, 60, and 72 hours post-dose
Plasma PK: Apparent Volume of Distribution (Vd/F) of ITF2357 and Its Metabolites
Vd/F was calculated as Dose/Kel x AUC0-inf for ITF2357 and Metabolites: ITF2374, ITF2375, ITF2440, ITF2563, and ITF2955 glucuronide.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, 36, 48, 60, and 72 hours post-dose
Plasma PK: Apparent Volume of Distribution (Vd/F) of Moxifloxacin
Vd/F was calculated as Dose/Kel x AUC0-inf for moxifloxacin.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, 36, 48, 60, and 72 hours post-dose
Urine PK: Cumulative Urinary Excretion From Time Zero to Time t (Ae0-t) for ITF2357 and Its Metabolites
Ae0-t was calculated as the sum of the amounts excreted over each collection interval. The amount excreted in the urine for each time interval is calculated as the urine concentration multiplied by the urine volume for ITF2357 and Metabolites: ITF2374, ITF2375, ITF2440, ITF2563, ITF2955 glucuronide.
Time frame: Pre-dose (within 2 hours before dosing), 0-8 hours, 8-24 hours, 24-48 hours, and 48-72 hours post-dose
Urine PK: Maximum Rate of Urinary Excretion (Rmax) for ITF2357 and Its Metabolites
Rmax was calculated by dividing the amount of drug excreted in each collection interval by the time over which it was collected for ITF2357 and Metabolites: ITF2374, ITF2375, ITF2440, ITF2563, ITF2955 glucuronide.
Time frame: Pre-dose (within 2 hours before dosing), 0-8 hours, 8-24 hours, 24-48 hours, and 48-72 hours post-dose
Urine PK: Time of Rmax (TRmax) for ITF2357 and Its Metabolites
TRmax was calculated as the midpoint of the collection interval during which Rmax occurred for ITF2357 and Metabolites: ITF2374, ITF2375, ITF2440, ITF2563, ITF2955 glucuronide.
Time frame: Pre-dose (within 2 hours before dosing), 0-8 hours, 8-24 hours, 24-48 hours, and 48-72 hours post-dose
Urine PK: Renal Clearance (Clr) for ITF2357 and Its Metabolites
Clr was calculated as Ae0-t / AUC0-t (plasma) for ITF2357 and Metabolites: ITF2374, ITF2375, ITF2440, ITF2563, ITF2955 glucuronide.
Time frame: Pre-dose (within 2 hours before dosing), 0-8 hours, 8-24 hours, 24-48 hours, and 48-72 hours post-dose
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs
Adverse event (AE) was defined as any untoward medical occurrence in a subject or clinical investigation participant administered a pharmaceutical product and which did not necessarily have a causal relationship with the study drug. Serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; required initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAE were defined as an AEs following the start of treatment or AEs increasing in severity during treatment. TEAEs include both serious and non-serious TEAEs.
Time frame: Baseline up to 44 days
Number of Treatment-Related TEAEs
Adverse event (AE) was defined as any untoward medical occurrence in a subject or clinical investigation participant administered a pharmaceutical product and which did not necessarily have a causal relationship with the study drug. Any AEs which occurred due to study drug treatment are reported as Treatment-related AEs. Number of treatment related TEAEs were reported.
Time frame: Baseline up to 44 days
Number of TEAEs Based on Severity
All AEs were analyzed using National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0 and were graded as Grade 1: mild asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated, Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living (ADL), Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL, Grade 4: Life-threatening consequences; urgent intervention indicated, Grade 5: death related AE, where higher grade indicated more severe condition. Number of TEAEs based on severity were reported.
Time frame: Baseline up to 44 days
Number of Participants With Clinically Significant Changes in Vital Signs
Vital signs, including semi supine blood pressure, pulse rate, respiratory rate, weight, and oral temperature were assessed. Clinical significance was decided by the investigator. Number of participants with clinically significant change from baseline in vital signs were reported.
Time frame: Baseline up to 44 days
Number of Participants With Clinically Significant Changes in Clinical Laboratory Parameters
Clinical laboratory parameters included biochemistry, hematology, and urinalysis. Clinical significance was decided by the investigator. Number of participants with clinically significant change from baseline in clinical laboratory parameters were reported.
Time frame: Baseline up to 44 days
Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Findings
ECG parameters included rhythm, ventricular rate, PR interval, QRS duration, and QT interval. Clinical significance was decided by the investigator. Number of participants with clinically significant change from baseline in ECG were reported.
Time frame: Baseline up to 44 days
The study was conducted at a single center in Canada. A total of 34 healthy non-smoker were screened in the study, of which 31 participants were enrolled and received the study treatment. Screen failures were mainly due to not meeting inclusion criteria.
| Milestone | Sequence TSTPM | Sequence STMTP | Sequence PTMST | Sequence MPSTT | Sequence STPTM | Sequence PMSTT | Sequence TSTMP | Sequence MTPST | Sequence PTSTM | Sequence TMPST | Sequence STPMT | Sequence MSTTP |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 1 | 1 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Completed | 1 | 1 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Sequence TSTPM | Sequence STMTP | Sequence PTMST | Sequence MPSTT | Sequence STPTM | Sequence PMSTT | Sequence TSTMP | Sequence MTPST | Sequence PTSTM | Sequence TMPST | Sequence STPMT | Sequence MSTTP |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 1 | 1 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Completed | 1 | 1 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Sequence TSTPM | Sequence STMTP | Sequence PTMST | Sequence MPSTT | Sequence STPTM | Sequence PMSTT | Sequence TSTMP | Sequence MTPST | Sequence PTSTM | Sequence TMPST | Sequence STPMT | Sequence MSTTP |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 1 | 1 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Completed | 1 | 1 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Sequence TSTPM | Sequence STMTP | Sequence PTMST | Sequence MPSTT | Sequence STPTM | Sequence PMSTT | Sequence TSTMP | Sequence MTPST | Sequence PTSTM | Sequence TMPST | Sequence STPMT | Sequence MSTTP |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 1 | 1 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Completed | 1 | 1 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Sequence TSTPM | Sequence STMTP | Sequence PTMST | Sequence MPSTT | Sequence STPTM | Sequence PMSTT | Sequence TSTMP | Sequence MTPST | Sequence PTSTM | Sequence TMPST | Sequence STPMT | Sequence MSTTP |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 1 | 1 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Completed | 1 | 1 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Sequence TSTPM | Sequence STMTP | Sequence PTMST | Sequence MPSTT | Sequence STPTM | Sequence PMSTT | Sequence TSTMP | Sequence MTPST | Sequence PTSTM | Sequence TMPST | Sequence STPMT | Sequence MSTTP |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 1 | 1 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Completed | 1 | 1 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Sequence TSTPM | Sequence STMTP | Sequence PTMST | Sequence MPSTT | Sequence STPTM | Sequence PMSTT | Sequence TSTMP | Sequence MTPST | Sequence PTSTM | Sequence TMPST | Sequence STPMT | Sequence MSTTP |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 1 | 1 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Completed | 1 | 1 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
The cardio-dynamic assessment was performed through 12-lead electrocardiogram (ECG) extracted from continuous recordings at pre-specified time points. Participants rested in supine position for at least 10 minutes prior to and 5 minutes after each time point for ECG extractions. The QT interval is the time from electrocardiogram Q wave to the end of the T wave corresponding to electrical systole. QT interval was corrected for heart rate using QTcF. Placebo-corrected change from baseline in QTcF (ΔΔQTcF) was calculated based on model-predicted effect.
| Milliseconds (msec) | Therapeutic Dose: ITF2357 100 mg | Supratherapeutic Dose: ITF2357 300 mg | Moxifloxacin |
|---|---|---|---|
| 0.5 hours post-dose | 1.0 ± 1.06 | 0.5 ± 1.04 | 10.2 ± 1.05 |
| 1 hours post-dose | 0.3 ± 1.01 | 0.8 ± 0.99 | 13.1 ± 1.00 |
| 1.5 hours Post-dose | 1.0 ± 0.99 | 2.7 ± 0.97 | 12.3 ± 0.98 |
| 2 hours Post-dose | 2.1 ± 1.00 | 4.3 ± 0.98 | 14.0 ± 0.99 |
| 2.5 hours Post-dose | 3.6 ± 1.17 | 6.1 ± 1.15 | 14.8 ± 1.16 |
| 3 hours Post-dose | 2.3 ± 1.06 | 6.6 ± 1.04 | 14.0 ± 1.05 |
| 3.5 hours Post-dose | 2.8 ± 1.14 | 9.1 ± 1.12 | 12.8 ± 1.13 |
| 4 hours Post-dose | 4.0 ± 1.13 | 10.4 ± 1.11 | 11.9 ± 1.12 |
| 5 hours Post-dose | 5.5 ± 2.11 | 13.6 ± 2.08 | 12.1 ± 2.09 |
| 6 hours Post-dose | 3.8 ± 1.82 | 11.4 ± 1.79 | 9.7 ± 1.81 |
| 7 hours Post-dose | 3.0 ± 1.76 | 9.2 ± 1.73 | 9.6 ± 1.74 |
| 8 hours Post-dose | 3.5 ± 1.57 | 11.5 ± 1.54 | 11.3 ± 1.55 |
| 12 hours Post-dose | 2.5 ± 1.85 | 10.2 ± 1.82 | 7.9 ± 1.83 |
| 24 hours Post-dose | 2.3 ± 1.62 | 11.0 ± 1.59 | 5.6 ± 1.61 |
| 36 hours Post-dose | -0.9 ± 1.86 | 1.5 ± 1.83 | 1.8 ± 1.84 |
The cardio-dynamic assessment was performed through 12-lead ECGs extracted from continuous recordings at pre-specified time points. Participants rested in supine position for at least 10 minutes prior to and 5 minutes after each time point for ECG extractions. QT interval was corrected for heart rate using Fridericia's correction (QTcF).
| msec | Therapeutic Dose: ITF2357 100 mg | Supratherapeutic Dose: ITF2357 300 mg | Moxifloxacin | Placebo |
|---|---|---|---|---|
| 0.5 hours Post-dose | -0.7 ± 0.88 | -1.3 ± 0.86 | 8.5 ± 0.87 | -1.8 ± 0.86 |
| 1 hours Post-dose | -0.3 ± 0.85 | 0.2 ± 0.83 | 12.5 ± 0.84 | -0.6 ± 0.83 |
| 1.5 hours Post-dose | 0.8 ± 0.84 | 2.5 ± 0.81 | 12.1 ± 0.82 | -0.2 ± 0.81 |
| 2 hours Post-dose | 1.3 ± 0.85 | 3.6 ± 0.82 | 13.2 ± 0.83 | -0.8 ± 0.82 |
| 2.5 hours Post-dose | 3.1 ± 0.95 | 5.5 ± 0.93 | 14.2 ± 0.94 | -0.5 ± 0.93 |
| 3 hours Post-dose | 2.9 ± 0.88 | 7.1 ± 0.86 | 14.5 ± 0.87 | 0.5 ± 0.86 |
| 3.5 hours Post-dose | 4.5 ± 0.93 | 10.7 ± 0.91 | 14.4 ± 0.92 | 1.6 ± 0.91 |
| 4 hours Post-dose | 6.0 ± 0.93 | 12.4 ± 0.90 | 13.9 ± 0.91 | 2.0 ± 0.90 |
| 5 hours Post-dose | 4.0 ± 1.58 | 12.1 ± 1.53 | 10.6 ± 1.56 | -1.5 ± 1.53 |
| 6 hours Post-dose | 0.4 ± 1.38 | 8.1 ± 1.34 | 6.3 ± 1.36 | -3.3 ± 1.34 |
| 7 hours Post-dose | -2.3 ± 1.34 | 3.8 ± 1.30 | 4.3 ± 1.32 | -5.3 ± 1.30 |
| 8 hours Post-dose | -2.8 ± 1.21 | 5.2 ± 1.18 | 5.0 ± 1.19 | -6.3 ± 1.18 |
| 12 hours Post-dose | 3.5 ± 1.40 | 11.2 ± 1.36 | 8.8 ± 1.38 | 1.0 ± 1.36 |
| 24 hours Post-dose | -1.5 ± 1.25 | 7.1 ± 1.21 | 1.7 ± 1.23 | -3.9 ± 1.21 |
| 36 hours Post-dose | -2.1 ± 1.41 | 0.2 ± 1.36 | 0.5 ± 1.38 | -1.3 ± 1.36 |
The cardio-dynamic assessment was performed through 12-lead ECGs extracted from continuous recordings at pre-specified time points. Participants rested in supine position for at least 10 minutes prior to and 5 minutes after each time point for ECG extractions. The PR interval is the time from the onset of the P-wave to the start of the next QRS complex, corresponding to the end of atrial depolarization and onset of ventricular depolarization.
| msec | Therapeutic Dose: ITF2357 100 mg | Supratherapeutic Dose: ITF2357 300 mg | Moxifloxacin | Placebo |
|---|---|---|---|---|
| 0.5 hours Post-dose | 0.0 ± 0.83 | -0.7 ± 0.81 | 0.1 ± 0.82 | 0.2 ± 0.81 |
| 1 hours Post-dose | 0.4 ± 1.04 | 0.7 ± 1.01 | -0.3 ± 1.02 | 2.3 ± 1.01 |
| 1.5 hours Post-dose | -1.4 ± 1.03 | -0.3 ± 1.00 | -0.4 ± 1.01 | 1.1 ± 1.00 |
| 2 hours Post-dose | 0.4 ± 1.04 | -1.3 ± 1.01 | -0.1 ± 1.02 | 1.6 ± 1.01 |
| 2.5 hours Post-dose | -2.4 ± 1.03 | -2.3 ± 1.00 | 0.8 ± 1.00 | -1.9 ± 1.01 |
| 3 hours Post-dose | -1.3 ± 1.03 | -1.6 ± 1.00 | -1.3 ± 1.01 | 0.2 ± 1.00 |
| 3.5 hours Post-dose | -2.6 ± 0.97 | -2.8 ± 0.94 | -2.0 ± 0.95 | 0.1 ± 0.94 |
| 4 hours Post-dose | -2.2 ± 1.04 | -3.4 ± 1.01 | -2.6 ± 1.03 | 0.1 ± 1.01 |
| 5 hours Post-dose | -5.3 ± 1.20 | -7.3 ± 1.16 | -6.0 ± 1.18 | -3.2 ± 1.16 |
| 6 hours Post-dose | -7.4 ± 1.30 | -9.3 ± 1.26 | -8.2 ± 1.28 | -5.5 ± 1.26 |
| 7 hours Post-dose | -7.2 ± 1.30 | -9.8 ± 1.26 | -8.0 ± 1.28 | -5.5 ± 1.26 |
| 8 hours Post-dose | -7.4 ± 1.16 | -9.0 ± 1.13 | -7.5 ± 1.15 | -5.2 ± 1.13 |
| 12 hours Post-dose | -5.8 ± 1.39 | -7.9 ± 1.35 | -6.7 ± 1.37 | -3.1 ± 1.35 |
| 24 hours Post-dose | -3.7 ± 1.32 | -3.8 ± 1.28 | 2.1 ± 1.30 | -0.9 ± 1.28 |
| 36 hours Post-dose | -7.8 ± 1.39 | -9.3 ± 1.34 | -3.3 ± 1.36 | -2.6 ± 1.34 |
The cardio-dynamic assessment was performed through 12-lead ECGs extracted from continuous recordings at pre-specified time points. Participants rested in supine position for at least 10 minutes prior to and 5 minutes after each time point for ECG extractions. QRS interval is the time from electrocardiogram Q wave to the end of the S wave, corresponding to ventricle depolarization.
| msec | Therapeutic Dose: ITF2357 100 mg | Supratherapeutic Dose: ITF2357 300 mg | Moxifloxacin | Placebo |
|---|---|---|---|---|
| 0.5 hours Post-dose | -0.1 ± 0.14 | 0.1 ± 0.13 | 0.2 ± 0.14 | 0.2 ± 0.13 |
| 1 hours Post-dose | 0.2 ± 0.16 | 0.1 ± 0.16 | 0.4 ± 0.16 | 0.0 ± 0.16 |
| 1.5 hours Post-dose | 0.0 ± 0.16 | 0.0 ± 0.16 | -0.1 ± 0.16 | -0.1 ± 0.16 |
| 2 hours Post-dose | -0.1 ± 0.15 | 0.2 ± 0.15 | 0.2 ± 0.15 | 0.0 ± 0.15 |
| 2.5 hours Post-dose | -0.1 ± 0.17 | 0.2 ± 0.16 | 0.3 ± 0.16 | 0.1 ± 0.16 |
| 3 hours Post-dose | 0.1 ± 0.17 | 0.4 ± 0.17 | 0.3 ± 0.17 | 0.3 ± 0.17 |
| 3.5 hours Post-dose | 0.1 ± 0.18 | 0.5 ± 0.17 | 0.1 ± 0.18 | 0.3 ± 0.17 |
| 4 hours Post-dose | 0.1 ± 0.20 | 0.4 ± 0.19 | 0.3 ± 0.20 | 0.2 ± 0.19 |
| 5 hours Post-dose | 0.1 ± 0.27 | 0.5 ± 0.26 | 0.3 ± 0.27 | 0.5 ± 0.26 |
| 6 hours Post-dose | -0.4 ± 0.24 | -0.3 ± 0.24 | -0.4 ± 0.24 | -0.2 ± 0.24 |
| 7 hours Post-dose | -0.7 ± 0.24 | -0.6 ± 0.23 | -0.5 ± 0.23 | -0.2 ± 0.23 |
| 8 hours Post-dose | -0.5 ± 0.22 | 0.1 ± 0.21 | -0.2 ± 0.21 | -0.2 ± 0.21 |
| 12 hours Post-dose | 0.2 ± 0.30 | -0.2 ± 0.29 | 0.1 ± 0.29 | 0.3 ± 0.29 |
| 24 hours Post-dose | -0.3 ± 0.39 | 0.1 ± 0.38 | -0.5 ± 0.39 | -0.3 ± 0.38 |
| 36 hours Post-dose | -0.4 ± 0.27 | -0.4 ± 0.26 | -0.5 ± 0.26 | -0.3 ± 0.26 |
The cardio-dynamic assessment was performed through 12-lead ECGs extracted from continuous recordings at pre-specified time points. Participants rested in supine position for at least 10 minutes prior to and 5 minutes after each time point for ECG extractions. Baseline is defined as the last results (scheduled or unscheduled) obtained prior to drug administration in each period.
| beats per minute (bpm) | Therapeutic Dose: ITF2357 100 mg | Supratherapeutic Dose: ITF2357 300 mg | Moxifloxacin | Placebo |
|---|---|---|---|---|
| 0.5 hours Post-dose | 0.6 ± 0.76 | 1.1 ± 0.75 | 1.3 ± 0.75 | 0.5 ± 0.75 |
| 1 hours Post-dose | 1.2 ± 0.85 | 2.8 ± 0.83 | 2.3 ± 0.84 | 1.1 ± 0.83 |
| 1.5 hours Post-dose | 3.3 ± 0.85 | 5.1 ± 0.83 | 1.9 ± 0.84 | 1.1 ± 0.84 |
| 2 hours Post-dose | 3.7 ± 0.86 | 7.8 ± 0.84 | 1.4 ± 0.85 | 1.1 ± 0.84 |
| 2.5 hours Post-dose | 3.8 ± 0.99 | 9.9 ± 0.97 | 0.9 ± 0.98 | 0.5 ± 0.97 |
| 3 hours Post-dose | 4.3 ± 0.86 | 10.5 ± 0.84 | 1.4 ± 0.85 | 0.7 ± 0.84 |
| 3.5 hours Post-dose | 4.0 ± 0.89 | 9.9 ± 0.87 | 2.2 ± 0.88 | 0.1 ± 0.87 |
| 4 hours Post-dose | 4.3 ± 0.94 | 11.0 ± 0.92 | 2.3 ± 0.93 | 1.3 ± 0.92 |
| 5 hours Post-dose | 15.0 ± 1.00 | 22.1 ± 0.98 | 10.6 ± 0.99 | 10.5 ± 0.98 |
| 6 hours Post-dose | 12.4 ± 1.10 | 21.7 ± 1.07 | 10.2 ± 1.08 | 10.4 ± 1.07 |
| 7 hours Post-dose | 8.2 ± 1.04 | 17.0 ± 1.02 | 7.5 ± 1.03 | 6.7 ± 1.02 |
| 8 hours Post-dose | 7.4 ± 0.88 | 14.0 ± 0.86 | 6.2 ± 0.87 | 5.6 ± 0.86 |
| 12 hours Post-dose | 9.5 ± 1.14 | 12.7 ± 1.11 | 10.6 ± 1.13 | 10.6 ± 1.11 |
| 24 hours Post-dose | 0.6 ± 0.80 | 2.1 ± 0.79 | 1.6 ± 0.80 | 2.2 ± 0.79 |
| 36 hours Post-dose | 9.1 ± 1.18 | 8.1 ± 1.15 | 10.2 ± 1.16 | 9.9 ± 1.15 |
Placebo-corrected change from Baseline in PR, (ΔΔPR) was calculated based on model-predicted effect. PR interval was the time between the beginning of the P wave and the start of the QRS interval, corresponding to the end of atrial depolarization and onset of ventricular depolarization.
| msec | Therapeutic Dose: ITF2357 100 mg | Supratherapeutic Dose: ITF2357 300 mg | Moxifloxacin |
|---|---|---|---|
| 0.5 hours Post-dose | -0.2 ± 1.02 | -0.9 ± 1.00 | -0.1 ± 1.01 |
| 1 hour Post-dose | -1.9 ± 1.34 | -1.6 ± 1.31 | -2.6 ± 1.32 |
| 1.5 hours Post-dose | -2.6 ± 1.33 | -1.5 ± 1.30 | -1.6 ± 1.31 |
| 2 hours Post-dose | -1.2 ± 1.34 | -2.9 ± 1.31 | -1.7 ± 1.32 |
| 2.5 hours Post-dose | -3.2 ± 1.32 | -3.1 ± 1.30 | -2.6 ± 1.31 |
| 3 hour Post-dose | -1.4 ± 1.32 | -1.8 ± 1.30 | -1.5 ± 1.31 |
| 3.5 hours Post-dose | -2.7 ± 1.23 | -2.9 ± 1.21 | -2.1 ± 1.22 |
| 4 hours Post-dose | -2.3 ± 1.35 | -3.5 ± 1.32 | -2.6 ± 1.33 |
| 5 hours Post-dose | -2.1 ± 1.57 | -4.1 ± 1.55 | -2.8 ± 1.56 |
| 6 hours Post-dose | -1.9 ± 1.73 | -3.8 ± 1.70 | -2.7 ± 1.71 |
| 7 hours Post-dose | -1.7 ± 1.73 | -4.3 ± 1.70 | -2.5 ± 1.71 |
| 8 hours Post-dose | -2.2 ± 1.53 | -3.8 ± 1.50 | -2.3 ± 1.51 |
| 12 hours Post-dose | -2.7 ± 1.85 | -4.7 ± 1.82 | -3.6 ± 1.84 |
| 24 hours Post-dose | -2.8 ± 1.76 | -2.9 ± 1.73 | 3.0 ± 1.74 |
| 36 hours Post-dose | -5.2 ± 1.85 | -6.6 ± 1.82 | -0.7 ± 1.83 |
Placebo-corrected change from baseline for QRS interval, (ΔΔQRS) was calculated based on model-predicted effect. QRS interval is the time from Q wave to the end of the S wave, corresponding to ventricle depolarization.
| msec | Therapeutic Dose: ITF2357 100 mg | Supratherapeutic Dose: ITF2357 300 mg | Moxifloxacin |
|---|---|---|---|
| 0.5 hours Post-dose | -0.2 ± 0.17 | 0.0 ± 0.16 | 0.1 ± 0.17 |
| 1 hours Post-dose | 0.1 ± 0.21 | 0.1 ± 0.20 | 0.4 ± 0.20 |
| 1.5 hours Post-dose | 0.1 ± 0.21 | 0.1 ± 0.20 | 0.0 ± 0.20 |
| 2 hours Post-dose | 0.0 ± 0.19 | 0.2 ± 0.19 | 0.3 ± 0.19 |
| 2.5 hours Post-dose | -0.2 ± 0.21 | 0.1 ± 0.20 | 0.2 ± 0.21 |
| 3 hours Post-dose | -0.2 ± 0.22 | 0.1 ± 0.22 | 0.0 ± 0.22 |
| 3.5 hours Post-dose | -0.3 ± 0.23 | 0.2 ± 0.23 | -0.2 ± 0.23 |
| 4 hours Post-dose | 0.0 ± 0.26 | 0.2 ± 0.26 | 0.2 ± 0.26 |
| 5 hours Post-dose | -0.3 ± 0.37 | 0.0 ± 0.36 | -0.2 ± 0.36 |
| 6 hours Post-dose | -0.2 ± 0.32 | 0.0 ± 0.32 | -0.1 ± 0.32 |
| 7 hours Post-dose | -0.5 ± 0.32 | -0.4 ± 0.31 | -0.3 ± 0.31 |
| 8 hours Post-dose | -0.3 ± 0.28 | 0.2 ± 0.28 | 0.0 ± 0.28 |
| 12 hours Post-dose | 0.0 ± 0.40 | -0.5 ± 0.39 | -0.1 ± 0.40 |
| 24 hours Post-dose | 0.1 ± 0.54 | 0.4 ± 0.53 | -0.1 ± 0.53 |
| 36 hours Post-dose | -0.1 ± 0.36 | -0.1 ± 0.35 | -0.2 ± 0.36 |
Placebo-corrected change from baseline in HR, (ΔΔHR) was calculated based on model-predicted effect.
| bpm | Therapeutic Dose: ITF2357 100 mg | Supratherapeutic Dose: ITF2357 300 mg | Moxifloxacin |
|---|---|---|---|
| 0.5 hours Post-dose | 0.1 ± 0.73 | 0.6 ± 0.71 | 0.8 ± 0.72 |
| 1 hours Post-dose | 0.1 ± 0.89 | 1.6 ± 0.88 | 1.2 ± 0.88 |
| 1.5 hours Post-dose | 2.2 ± 0.90 | 4.0 ± 0.88 | 0.8 ± 0.89 |
| 2 hours Post-dose | 2.6 ± 0.92 | 6.7 ± 0.90 | 0.3 ± 0.91 |
| 2.5 hours Post-dose | 3.3 ± 1.15 | 9.3 ± 1.13 | 0.3 ± 1.14 |
| 3 hours Post-dose | 3.6 ± 0.91 | 9.8 ± 0.90 | 0.7 ± 0.91 |
| 3.5 hours Post-dose | 3.9 ± 0.96 | 9.8 ± 0.95 | 2.1 ± 0.96 |
| 4 hours Post-dose | 3.0 ± 1.06 | 9.7 ± 1.04 | 1.0 ± 1.05 |
| 5 hours Post-dose | 4.5 ± 1.17 | 11.6 ± 1.15 | 0.1 ± 1.16 |
| 6 hours Post-dose | 1.9 ± 1.32 | 11.2 ± 1.29 | -0.3 ± 1.31 |
| 7 hours Post-dose | 1.4 ± 1.23 | 10.2 ± 1.21 | 0.7 ± 1.22 |
| 8 hours Post-dose | 1.9 ± 0.95 | 8.5 ± 0.93 | 0.7 ± 0.94 |
| 12 hours Post-dose | -1.1 ± 1.39 | 2.1 ± 1.37 | -0.1 ± 1.38 |
| 24 hours Post-dose | -1.6 ± 0.82 | -0.2 ± 0.80 | -0.7 ± 0.81 |
| 36 hours Post-dose | -0.8 ± 1.45 | -1.8 ± 1.43 | 0.3 ± 1.44 |
QTcF: Treatment-emergent value of greater than (\>) 450 and less than or equal to (\<=) 480 ms when not present at Baseline (new onset). Treatment-emergent value of \> 480 and \<= 500 ms when not present at Baseline (new onset). Treatment-emergent value of \> 500 ms when not present at Baseline (new onset). Increase of QTcF (ΔQTcF) from Baseline of \> 30 and \<= 60 ms. Increase of QTcF from Baseline \> 60 ms HR: Decrease of HR from Baseline \> 25% resulting in HR less than (\<) 50 bpm. Increase of HR from Baseline \> 25% resulting in HR \> 100 bpm. PR: Increase of PR from Baseline \> 25% resulting in PR \> 210 ms. QRS: Increase of QRS from Baseline \> 25% resulting in QRS \> 120 ms.
| Participants | Therapeutic Dose: ITF2357 100 mg | Supratherapeutic Dose: ITF2357 300 mg | Moxifloxacin | Placebo |
|---|---|---|---|---|
| QTcF > 450 and <= 480 ms | 0 | 1 | 2 | 0 |
| QTcF > 480 and <= 500 ms | 0 | 0 | 0 | 0 |
| QTcF > 500 ms | 0 | 0 | 0 | 0 |
| ΔQTcF > 30 and <= 60 ms | 0 | 2 | 2 | 0 |
| ΔQTcF > 60 ms | 0 | 0 | 0 | 0 |
| HR < 50 (bpm) with a decrease in ΔHR > 25% | 0 | 0 | 0 | 0 |
| HR > 100 (bpm) with an increase in ΔHR > 25% | 0 | 0 | 0 | 0 |
| PR > 210 (ms) with an increase in ΔPR > 25% | 0 | 0 | 0 | 0 |
| QRS > 120 (ms) with an increase in ΔQRS > 25% | 0 | 0 | 0 | 0 |
T-wave abnormalities were categorized as follows: Normal T wave (+): Any positive T wave not meeting any criterion below. Flat T wave: T amplitude \< 1 mm (either positive or negative) including flat isoelectric line. Notched T wave (+): Presence of notch(es) of at least 0.05 mV amplitude on ascending or descending arm of the positive T wave. Biphasic: T wave that contains a second component with an opposite phase that is at least 0.1 mV deep (both positive/negative and negative/positive and polyphasic T waves included). Normal T wave (-): T amplitude that is negative, without biphasic T wave or notches. Notched T wave (-): Presence of notch(es) of at least 0.05 mV amplitude on descending or ascending arm of the negative T wave. U waves: Presence of abnormal U waves.
| Participants | Therapeutic Dose: ITF2357 100 mg | Supratherapeutic Dose: ITF2357 300 mg | Moxifloxacin | Placebo |
|---|---|---|---|---|
| Flat | 0 | 0 | 0 | 0 |
| Notched (+) | 0 | 0 | 0 | 0 |
| Biphasic | 0 | 0 | 0 | 0 |
| Normal (-) | 0 | 0 | 0 | 0 |
| Notched (-) | 0 | 0 | 0 | 0 |
| U-Wave presence | 0 | 0 | 0 | 0 |
The area under the concentration time curve (AUC) from time zero (= dosing time) to the last sampling time (tlast) at which the concentration is at or above the lower limit of quantification. AUC0-t was calculated using the mixed log-linear trapezoidal rule (linear up, log down). AUC0-t of ITF2357 and metabolites: ITF2374, ITF2375, ITF2440, ITF2563, and ITF2955 glucuronide were reported.
| hours*nanograms per milliliter (h*ng/mL) | Therapeutic Dose: ITF2357 100 mg | Supratherapeutic Dose: ITF2357 300 mg |
|---|---|---|
| ITF2357 | 596.10 ± 22.57 | 2313.44 ± 20.53 |
| ITF2374 | 363.55 ± 63.83 | 1296.22 ± 59.65 |
| ITF2375 | 2672.92 ± 54.88 | 9599.11 ± 52.70 |
| ITF2440 | 5696.28 ± 23.36 | 18577.74 ± 21.34 |
| ITF2563 | 1247.92 ± 23.58 | 3563.33 ± 20.59 |
| ITF2955 glucuronide | 1.53 ± 78.00 | 15.89 ± 47.69 |
The area under the concentration time curve (AUC) from time zero (= dosing time) to the last sampling time (tlast) at which the concentration is at or above the lower limit of quantification. AUC0-t was calculated using the mixed log-linear trapezoidal rule (linear up, log down).
| h*ng/mL | Moxifloxacin |
|---|---|
| Plasma PK: Area Under the Concentration-Time Curve From Time Zero to the Last Measurable Concentration (AUC0-t) of Moxifloxacin | 27077.52 ± 16.17 |
AUC0-12 was calculated using the trapezoidal method for ITF2357 and metabolites: ITF2374, ITF2375, ITF2440, ITF2563, and ITF2955 glucuronide. AUC0-12:: of ITF2357 and its metabolites: ITF2374, ITF2375, ITF2440, ITF2563, and ITF2955 glucuronide were reported.
| h*ng/mL | Therapeutic Dose: ITF2357 100 mg | Supratherapeutic Dose: ITF2357 300 mg |
|---|---|---|
| ITF2357 | 480.70 ± 114.09 | 1893.60 ± 423.33 |
| ITF2374 | 178.10 ± 81.57 | 607.16 ± 258.73 |
| ITF2375 | 1680.76 ± 725.80 | 6018.02 ± 2430.06 |
| ITF2440 | 1448.97 ± 362.63 | 3924.21 ± 1130.05 |
| ITF2563 | 299.77 ± 85.39 | 776.22 ± 259.98 |
| ITF2955 glucuronide | 0.88 ± 1.62 | 18.08 ± 8.39 |
AUC0-12 was calculated using the trapezoidal method for Moxifloxacin.
| h*ng/mL | Moxifloxacin |
|---|---|
| Plasma PK: Area Under the Concentration-Time Curve From Time Zero to 12 Hours (AUC0-12) of Moxifloxacin | 13625.09 ± 2733.45 |
AUC0-inf was calculated as AUC0-t + Clast/Kel, where Clast is the last measurable concentration. Elimination rate constant (Kel),was defined as the negative of the estimated slope of the linear regression of the in-transformed concentration versus time profile in the terminal elimination phase. AUC0-inf of ITF2357 and metabolites: ITF2374, ITF2375, ITF2440, ITF2563, and ITF2955 glucuronide were reported.
| h*ng/mL | Therapeutic Dose: ITF2357 100 mg | Supratherapeutic Dose: ITF2357 300 mg |
|---|---|---|
| ITF2357 | 626.57 ± 139.54 | 2383.27 ± 484.72 |
| ITF2374 | 475.82 ± 318.25 | 1555.70 ± 986.40 |
| ITF2375 | 3246.97 ± 1806.52 | 11373.93 ± 6045.30 |
| ITF2440 | 6196.74 ± 1400.60 | 19920.16 ± 4134.67 |
| ITF2563 | 1357.46 ± 290.51 | 3864.88 ± 757.94 |
| ITF2955 glucuronide | 10.20 | 20.68 ± 9.56 |
AUC0-inf was calculated as AUC0-t + Clast/Kel, where Clast is the last measurable concentration for Moxifloxacin.
| h*ng/mL | Moxifloxacin |
|---|---|
| Plasma PK: Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of Moxifloxacin | 28327.15 ± 4616.50 |
Residual area was calculated as 100\*(1- AUC0-t / AUC0-inf) for ITF2357 and Metabolites: ITF2374, ITF2375, ITF2440, ITF2563, and ITF2955 glucuronide.
| Percentage of residual area | Therapeutic Dose: ITF2357 100 mg | Supratherapeutic Dose: ITF2357 300 mg |
|---|---|---|
| ITF2357 | 2.63 ± 0.84 | 0.95 ± 0.36 |
| ITF2374 | 8.49 ± 4.23 | 3.72 ± 2.82 |
| ITF2375 | 3.45 ± 2.28 | 1.70 ± 1.25 |
| ITF2440 | 5.81 ± 3.09 | 4.69 ± 3.58 |
| ITF2563 | 6.04 ± 4.53 | 5.95 ± 4.42 |
| ITF2955 glucuronide | 66.07 | 24.01 ± 6.03 |
Residual area was calculated as 100\*(1- AUC0-t / AUC0-inf) for moxifloxacin.
| Percentage of residual area | Moxifloxacin |
|---|---|
| Plasma PK: Percentage of Residual Area for Moxifloxacin | 2.81 ± 48.66 |
Cmax was calculated for ITF2357 and Metabolites: ITF2374, ITF2375, ITF2440, ITF2563, and ITF2955 glucuronide. Cmax was taken directly from the observed concentration-time curve.
| ng/mL | Therapeutic Dose: ITF2357 100 mg | Supratherapeutic Dose: ITF2357 300 mg |
|---|---|---|
| ITF2357 | 102.84 ± 30.55 | 409.65 ± 133.74 |
| ITF2374 | 24.39 ± 11.01 | 81.59 ± 32.93 |
| ITF2375 | 258.64 ± 111.23 | 820.75 ± 273.52 |
| ITF2440 | 195.23 ± 45.41 | 602.02 ± 142.15 |
| ITF2563 | 43.90 ± 13.03 | 123.27 ± 31.02 |
| ITF2955 glucuronide | 0.42 ± 0.62 | 4.41 ± 1.70 |
Cmax was calculated for moxifloxacin. Cmax was taken directly from the observed concentration-time curve.
| ng/mL | Moxifloxacin |
|---|---|
| Plasma PK: Maximum Observed Plasma Concentration (Cmax) of Moxifloxacin | 1789.49 ± 498.08 |
Tmax was calculated for ITF2357 and Metabolites: ITF2374, ITF2375, ITF2440, ITF2563, and ITF2955 glucuronide. The time to reach the maximum observed plasma concentration obtained directly from plasma concentration time curve.
| hours | Therapeutic Dose: ITF2357 100 mg | Supratherapeutic Dose: ITF2357 300 mg |
|---|---|---|
| ITF2357 | 2.139 (1.099 to 3.355) | 2.158 (1.165 to 5.092) |
| ITF2374 | 5.098 (5.089 to 6.298) | 5.634 (5.093 to 7.094) |
| ITF2375 | 3.610 (2.153 to 4.101) | 4.094 (2.599 to 5.101) |
| ITF2440 | 12.144 (8.090 to 12.238) | 12.152 (12.134 to 12.228) |
| ITF2563 | 12.146 (7.100 to 12.238) | 12.152 (8.090 to 12.228) |
| ITF2955 glucuronide | 0 (0 to 3.604) | 2.606 (1.596 to 4.093) |
Tmax was calculated for Moxifloxacin. The time to reach the maximum observed plasma concentration obtained directly from plasma concentration time curve.
| hours | Moxifloxacin |
|---|---|
| Plasma PK: Time of Observed Cmax (Tmax) of Moxifloxacin | 2.327 (0.615 to 4.095) |
Kel was defined as the negative of the estimated slope of the linear regression of the ln-transformed concentration versus time profile in the terminal elimination phase. Kel was calculated for ITF2357 and Metabolites: ITF2374, ITF2375, ITF2440, ITF2563, andITF2955 glucuronide.
| fraction per hour | Therapeutic Dose: ITF2357 100 mg | Supratherapeutic Dose: ITF2357 300 mg |
|---|---|---|
| ITF2357 | 0.0923 ± 0.0198 | 0.0652 ± 0.0146 |
| ITF2374 | 0.0570 ± 0.0141 | 0.0549 ± 0.0175 |
| ITF2375 | 0.0585 ± 0.0157 | 0.0667 ± 0.0130 |
| ITF2440 | 0.0508 ± 0.0126 | 0.0530 ± 0.0124 |
| ITF2563 | 0.0499 ± 0.0138 | 0.0498 ± 0.0156 |
| ITF2955 glucuronide | 0.1514 | 0.2886 ± 0.0944 |
Kel was defined as the negative of the estimated slope of the linear regression of the ln-transformed concentration versus time profile in the terminal elimination phase. Kel was calculated for Moxifloxacin.
| fraction per hour | Moxifloxacin |
|---|---|
| Plasma PK: Elimination Rate Constant (Kel) of Moxifloxacin | 0.0493 ± 0.0091 |
T½ el was calculated as ln(2)/kel for ITF2357 and Metabolites : ITF2374, ITF2375, ITF2440, ITF2563, ITF2955 glucuronide, and Moxifloxacin.
| hours | Therapeutic Dose: ITF2357 100 mg | Supratherapeutic Dose: ITF2357 300 mg |
|---|---|---|
| ITF2357 | 7.25 (5.47 to 13.69) | 11.19 (6.26 to 16.35) |
| ITF2374 | 12.63 (9.08 to 26.30) | 12.49 (8.27 to 22.07) |
| ITF2375 | 12.31 (8.38 to 16.77) | 10.71 (7.97 to 13.86) |
| ITF2440 | 12.91 (9.94 to 22.65) | 13.07 (9.48 to 20.87) |
| ITF2563 | 13.47 (9.76 to 29.08) | 13.33 (9.56 to 23.00) |
| ITF2955 glucuronide | 4.58 (4.58 to 4.58) | 2.27 (1.62 to 4.49) |
T½ el was calculated as ln(2)/kel for moxifloxacin.
| hours | Moxifloxacin |
|---|---|
| Plasma PK: Elimination Half-life (T½ el) of Moxifloxacin | 13.97 (9.96 to 20.83) |
CL/F was calculated as Dose/AUC0-inf for ITF2357 and Metabolites: ITF2374, ITF2375, ITF2440, ITF2563, and ITF2955 glucuronide.
| liters per hour | Therapeutic Dose: ITF2357 100 mg | Supratherapeutic Dose: ITF2357 300 mg |
|---|---|---|
| ITF2357 | 167.12 ± 36.40 | 131.11 ± 27.51 |
| ITF2374 | 296.86 ± 172.71 | 251.84 ± 124.72 |
| ITF2375 | 43.11 ± 27.80 | 36.69 ± 23.96 |
| ITF2440 | 16.94 ± 4.01 | 15.73 ± 3.60 |
| ITF2563 | 76.77 ± 16.33 | 80.71 ± 17.61 |
| ITF2955 glucuronide | 9808.03 | 16631.81 ± 5576.18 |
CL/F was calculated as Dose/AUC0-inf for moxifloxacin.
| liters per hour | Moxifloxacin |
|---|---|
| Plasma PK: Apparent Total Body Clearance (CL/F) of Moxifloxacin | 14.49 ± 2.39 |
Vd/F was calculated as Dose/Kel x AUC0-inf for ITF2357 and Metabolites: ITF2374, ITF2375, ITF2440, ITF2563, and ITF2955 glucuronide.
| liters | Therapeutic Dose: ITF2357 100 mg | Supratherapeutic Dose: ITF2357 300 mg |
|---|---|---|
| ITF2357 | 1897.03 ± 588.15 | 2125.49 ± 764.32 |
| ITF2374 | 5094.92 ± 2676.37 | 5027.46 ± 3106.93 |
| ITF2375 | 795.34 ± 636.25 | 576.42 ± 436.72 |
| ITF2440 | 354.01 ± 123.39 | 311.58 ± 96.04 |
| ITF2563 | 1702.58 ± 749.67 | 1757.38 ± 556.98 |
| ITF2955 glucuronide | 64779.37 | 58366.39 ± 12977.61 |
Vd/F was calculated as Dose/Kel x AUC0-inf for moxifloxacin.
| liters | Moxifloxacin |
|---|---|
| Plasma PK: Apparent Volume of Distribution (Vd/F) of Moxifloxacin | 303.02 ± 72.21 |
Ae0-t was calculated as the sum of the amounts excreted over each collection interval. The amount excreted in the urine for each time interval is calculated as the urine concentration multiplied by the urine volume for ITF2357 and Metabolites: ITF2374, ITF2375, ITF2440, ITF2563, ITF2955 glucuronide.
| Nanograms (ng) | Therapeutic Dose: ITF2357 100 mg | Supratherapeutic Dose: ITF2357 300 mg |
|---|---|---|
| ITF2357 | 1304747.81 ± 444627.39 | 4284095.88 ± 1031461.74 |
| ITF2374 | 1526630.97 ± 820295.42 | 4634585.90 ± 2469826.92 |
| ITF2375 | 330005.73 ± 244198.09 | 1051751.97 ± 702770.77 |
| ITF2440 | 20496643.63 ± 3002369.96 | 55319154.12 ± 9058968.83 |
| ITF2563 | 9746260.02 ± 1204246.03 | 27259547.79 ± 4213356.29 |
| ITF2955 glucuronide | 13456.18 ± 3086.53 | 66582.99 ± 18731.80 |
Rmax was calculated by dividing the amount of drug excreted in each collection interval by the time over which it was collected for ITF2357 and Metabolites: ITF2374, ITF2375, ITF2440, ITF2563, ITF2955 glucuronide.
| Nanogram per hour (ng/h) | Therapeutic Dose: ITF2357 100 mg | Supratherapeutic Dose: ITF2357 300 mg |
|---|---|---|
| ITF2357 | 304920.74 ± 327302.13 | 1224735.12 ± 922878.78 |
| ITF2374 | 155698.10 ± 166313.02 | 536094.03 ± 361645.28 |
| ITF2375 | 51562.37 ± 46045.34 | 182276.01 ± 172602.20 |
| ITF2440 | 1323571.78 ± 414580.11 | 3469056.76 ± 1554749.72 |
| ITF2563 | 712846.46 ± 298304.19 | 1986177.40 ± 904296.76 |
| ITF2955 glucuronide | 5170.46 ± 4743.78 | 25858.22 ± 23838.45 |
TRmax was calculated as the midpoint of the collection interval during which Rmax occurred for ITF2357 and Metabolites: ITF2374, ITF2375, ITF2440, ITF2563, ITF2955 glucuronide.
| hours | Therapeutic Dose: ITF2357 100 mg | Supratherapeutic Dose: ITF2357 300 mg |
|---|---|---|
| ITF2357 | 1.84 (0.34 to 3.77) | 1.49 (0.36 to 9.39) |
| ITF2374 | 4.40 (0.34 to 11.01) | 1.49 (0.36 to 10.01) |
| ITF2375 | 1.84 (0.34 to 10.01) | 1.49 (0.36 to 9.39) |
| ITF2440 | 7.24 (0.34 to 11.01) | 6.65 (0.36 to 22.17) |
| ITF2563 | 7.24 (0.34 to 11.01) | 6.65 (0.36 to 10.01) |
| ITF2955 glucuronide | 1.84 (0.34 to 3.77) | 1.49 (0.36 to 3.79) |
Clr was calculated as Ae0-t / AUC0-t (plasma) for ITF2357 and Metabolites: ITF2374, ITF2375, ITF2440, ITF2563, ITF2955 glucuronide.
| L/h | Therapeutic Dose: ITF2357 100 mg | Supratherapeutic Dose: ITF2357 300 mg |
|---|---|---|
| ITF2357 | 2127.55 ± 402.63 | 1859.30 ± 360.82 |
| ITF2374 | 3856.29 ± 979.36 | 3403.49 ± 1004.83 |
| ITF2375 | 103.35 ± 27.94 | 96.02 ± 29.26 |
| ITF2440 | 3629.92 ± 717.29 | 2994.15 ± 583.57 |
| ITF2563 | 7879.16 ± 1464.33 | 7666.41 ± 1279.54 |
| ITF2955 glucuronide | 16623.97 ± 22459.53 | 4215.01 ± 1176.29 |
Adverse event (AE) was defined as any untoward medical occurrence in a subject or clinical investigation participant administered a pharmaceutical product and which did not necessarily have a causal relationship with the study drug. Serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; required initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAE were defined as an AEs following the start of treatment or AEs increasing in severity during treatment. TEAEs include both serious and non-serious TEAEs.
| Participants | Therapeutic Dose: ITF2357 100 mg | Supratherapeutic Dose: ITF2357 300 mg | Placebo | Moxifloxacin |
|---|---|---|---|---|
| Participants with TEAEs | 5 | 15 | 4 | 6 |
| Participants with Serious TEAEs | 0 | 0 | 0 | 0 |
Adverse event (AE) was defined as any untoward medical occurrence in a subject or clinical investigation participant administered a pharmaceutical product and which did not necessarily have a causal relationship with the study drug. Any AEs which occurred due to study drug treatment are reported as Treatment-related AEs. Number of treatment related TEAEs were reported.
| number of events | Therapeutic Dose: ITF2357 100 mg | Supratherapeutic Dose: ITF2357 300 mg | Placebo | Moxifloxacin |
|---|---|---|---|---|
| Number of Treatment-Related TEAEs | 6 | 20 | 6 | 4 |
All AEs were analyzed using National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0 and were graded as Grade 1: mild asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated, Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living (ADL), Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL, Grade 4: Life-threatening consequences; urgent intervention indicated, Grade 5: death related AE, where higher grade indicated more severe condition. Number of TEAEs based on severity were reported.
| number of events | Therapeutic Dose: ITF2357 100 mg | Supratherapeutic Dose: ITF2357 300 mg | Placebo | Moxifloxacin |
|---|---|---|---|---|
| Mild | 6 | 21 | 8 | 6 |
| Moderate | 0 | 4 | 0 | 0 |
| Severe | 0 | 0 | 0 | 0 |
Vital signs, including semi supine blood pressure, pulse rate, respiratory rate, weight, and oral temperature were assessed. Clinical significance was decided by the investigator. Number of participants with clinically significant change from baseline in vital signs were reported.
| Participants | Therapeutic Dose: ITF2357 100 mg | Supratherapeutic Dose: ITF2357 300 mg | Placebo | Moxifloxacin |
|---|---|---|---|---|
| Number of Participants With Clinically Significant Changes in Vital Signs | 0 | 0 | 0 | 0 |
Clinical laboratory parameters included biochemistry, hematology, and urinalysis. Clinical significance was decided by the investigator. Number of participants with clinically significant change from baseline in clinical laboratory parameters were reported.
| Participants | Therapeutic Dose: ITF2357 100 mg | Supratherapeutic Dose: ITF2357 300 mg | Placebo | Moxifloxacin |
|---|---|---|---|---|
| Number of Participants With Clinically Significant Changes in Clinical Laboratory Parameters | 0 | 2 | 0 | 0 |
ECG parameters included rhythm, ventricular rate, PR interval, QRS duration, and QT interval. Clinical significance was decided by the investigator. Number of participants with clinically significant change from baseline in ECG were reported.
| Participants | Therapeutic Dose: ITF2357 100 mg | Supratherapeutic Dose: ITF2357 300 mg | Placebo | Moxifloxacin |
|---|---|---|---|---|
| Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Findings | 0 | 0 | 0 | 0 |
Collected over Baseline up to 44 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Therapeutic Dose: ITF2357 100 mg | 0/29 (0%) | 0/29 (0%) | 5/29 (17.2%) |
| Supratherapeutic Dose: ITF2357 300 mg | 0/31 (0%) | 0/31 (0%) | 15/31 (48.4%) |
| Placebo | 0/31 (0%) | 0/31 (0%) | 6/31 (19.4%) |
| Moxifloxacin | 0/31 (0%) | 0/31 (0%) | 4/31 (12.9%) |
| Event | Therapeutic Dose: ITF2357 100 mg | Supratherapeutic Dose: ITF2357 300 mg | Placebo | Moxifloxacin |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 0/29 | 5/31 | 0/31 | 2/31 |
| HeadacheNervous system disorders | 1/29 | 4/31 | 1/31 | 0/31 |
| Abdominal discomfortGastrointestinal disorders | 0/29 | 3/31 | 0/31 | 0/31 |
| DiarrhoeaGastrointestinal disorders | 2/29 | 1/31 | 2/31 | 0/31 |
| DizzinessNervous system disorders | 1/29 | 0/31 | 0/31 | 0/31 |
| Sensation of foreign bodyGeneral disorders | 1/29 | 0/31 | 0/31 | 0/31 |
| Back painMusculoskeletal and connective tissue disorders | 1/29 | 1/31 | 0/31 | 0/31 |
| Pain in jawMusculoskeletal and connective tissue disorders | 1/29 | 0/31 | 0/31 | 0/31 |
| Abdominal painGastrointestinal disorders | 0/29 | 1/31 | 1/31 | 0/31 |
| ConstipationGastrointestinal disorders | 0/29 | 1/31 | 0/31 | 1/31 |
Safety population included all participants who had received at least 1 dose of study drug (therapeutic and supratherapeutic doses of ITF2357, moxifloxacin, or placebo). All participants had multiple movement within the arms of the study at different levels and unique participants baseline was not analyzed, only overall participant data was planned, analyzed and reported to avoid double-counting.
| Age, Continuous(years) | All Participants |
|---|---|
| Mean | 40.6 ± 10.8 |
| Sex: Female, Male(Participants) | All Participants |
|---|---|
| Female | 12 |
| Male | 19 |
| Ethnicity (NIH/OMB)(Participants) | All Participants |
|---|---|
| Hispanic or Latino | 10 |
| Not Hispanic or Latino | 21 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | All Participants |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 3 |
| White | 27 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2021 to primary completion in Jun 2021, 2 months.
Results were first posted in Jan 2024, 2 years 6 months after primary completion.
Of 28 phase 1 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 35. This study's 2 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Givinostat
Muscular Dystrophy, Duchenne →